1. Home
  2. SPCX vs AMGN Comparison

SPCX vs AMGN Comparison

Compare SPCX & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Space Exploration Technologies Corp.

SPCX

Space Exploration Technologies Corp.

N/A

Current Price

$143.30

Market Cap

1.7T

Sector

Technology

ML Signal

N/A

Logo Amgen Inc.

AMGN

Amgen Inc.

HOLD

Current Price

$425.28

Market Cap

207.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCX
AMGN
Founded
N/A
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7T
207.9B
IPO Year
2026
2002

Fundamental Metrics

Financial Performance
Metric
SPCX
AMGN
Price
$143.30
$425.28
Analyst Decision
Hold
Analyst Count
0
19
Target Price
N/A
$351.05
AVG Volume (30 Days)
100.2M
2.5M
Earning Date
N/A
04-30-2026
Dividend Yield
N/A
2.98%
EPS Growth
N/A
88.23
EPS
N/A
7.71
Revenue
N/A
$25,424,000,000.00
Revenue This Year
N/A
$5.00
Revenue Next Year
N/A
$2.45
P/E Ratio
N/A
$54.39
Revenue Growth
N/A
8.83
52 Week Low
$104.83
$269.77
52 Week High
$176.75
$421.79

Technical Indicators

Market Signals
Indicator
SPCX
AMGN
Relative Strength Index (RSI) 56.64 75.13
Support Level $105.92 $336.77
Resistance Level $172.40 N/A
Average True Range (ATR) 9.96 11.22
MACD 4.09 1.58
Stochastic Oscillator 85.75 97.30

Price Performance

Historical Comparison
SPCX
AMGN

About SPCX Space Exploration Technologies Corp.

Founded in 2002 and commonly known as SpaceX, the Space Exploration Technologies Corporation designs, manufactures, and operates a family of reusable rockets to launch various payloads into Earth orbit for government and commercial customers. Starting in 2019, the company began launching a constellation of its own communication satellites to provide mobile broadband and wireless services under the Starlink brand. In early 2026, the company acquired xAI from its founder, Elon Musk, which operates a large language artificial intelligence model named Grok, a gigawatt-scale data center called Colossus, and the social media network X.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: